This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
PFENegative Net Change MRKPositive Net Change CSTLPositive Net Change ERASNegative Net Change
biotechs medical pharmaceuticals
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change AMGNPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
by Zacks Equity Research
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
MRKPositive Net Change EXELPositive Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?
by Zacks Equity Research
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
by Zacks Equity Research
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
HALOPositive Net Change CTMXNegative Net Change CSTLPositive Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
by Zacks Equity Research
Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.
REGNPositive Net Change PBYIPositive Net Change NTLANegative Net Change CTMXNegative Net Change
biotechs
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
JNJPositive Net Change CTMXNegative Net Change ARGXPositive Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
by Zacks Equity Research
NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.
TEVAPositive Net Change CPRXNegative Net Change HOTHNegative Net Change VIRNegative Net Change NMRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
by Zacks Equity Research
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
PBYIPositive Net Change CTMXNegative Net Change CSTLPositive Net Change VIRNegative Net Change
biotechs
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
by Zacks Equity Research
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.
RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change PBYIPositive Net Change
biotechs
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
SNYPositive Net Change BIIBNegative Net Change HALOPositive Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
NVOPositive Net Change LLYPositive Net Change HALOPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
by Zacks Equity Research
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
TEVAPositive Net Change HALOPositive Net Change CPRXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
by Zacks Equity Research
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
RPRXPositive Net Change AGIOPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs medical
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
by Zacks Equity Research
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
PBYIPositive Net Change CRMDPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs medical
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
by Zacks Equity Research
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
HALOPositive Net Change PCRXNegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
by Zacks Equity Research
Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.
HALOPositive Net Change PBYIPositive Net Change ATRANegative Net Change CSTLPositive Net Change
biotechs
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
by Zacks Equity Research
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
HALOPositive Net Change CTMXNegative Net Change HOTHNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Geron Stock Rallies More Than 60% in a Year: Here's Why
by Zacks Equity Research
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
GERNPositive Net Change HALOPositive Net Change PBYIPositive Net Change CSTLPositive Net Change
biotechs
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
by Zacks Equity Research
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
BIIBNegative Net Change PBYIPositive Net Change SLDBNegative Net Change LRMRPositive Net Change
biotechs
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death
by Sundeep Ganoria
The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.
MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change CVACPositive Net Change
biotechs medical pharmaceuticals vaccines
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
by Zacks Equity Research
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
GSKPositive Net Change PBYIPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs